Profile: EntreMed, Inc. is a clinical-stage pharmaceutical company developing a new generation of multi-mechanism drugs for the treatment of cancer and inflammatory diseases. Our drug candidates target disease cells and the blood vessels that nourish them. We develop & deliver therapeutic products based on the scientific expertise in angiogenesis, cell cycle regulation, cell signaling, and inflammation processes that are vital to the progression of cancer & other diseases. Our ENMD-2076 is an Aurora A and angiogenic kinase inhibitor for the treatment of cancer.